Objective : Objective: To assess and compare the impact of biologic agents used to treat rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), and other autoimmune diseases on different domains of health-related quality of life—physical, psychological, mental, and social aspects of well-being that are influenced by disease. Design : A prospective observational cohort study assessed the effect of biologic therapy on HRQOL for patients in Alexandria Main University Hospital, Alexandria, Egypt. It was conducted between December 2020 and August 2021. The drugs tested were Adalimumab atto (Amjevita), a monoclonal anti-tumor necrosis factor alpha; Secukinumab (cosentyx), a monoclonal antibody to interleukin-17A; and Etanercept (Enbrel), a tumor necrosis factor (TNF) blocker. Adalimumab (humira) tumor necrosis factor (TNF) blockers, Infliximab (remicade) tumor necrosis factor (TNF)-alpha blockers, and Golimumab (simponi) tumor necrosis factor (TNF) inhibitors. Patient-reported outcomes on 70 participants were done using the validated Arabic version of the SF-36 questionnaire in the form of an oral interview to assess physical, social functioning, role limitations, emotional state, and general health.